Key facts
- NK:IO’s last known valuation is $9.2M.
- It has raised $6.7M; the latest was Seed Round ($1.1M) in May 2024.
- Notable investors include Innovate UK, Future Planet Capital, Parkwalk Advisors, Cambridge Angels, UK Innovation & Science Seed Fund — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for NK:IO
- ·The full record, as it builds
Funding rounds
No funding rounds for NK:IO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NK:IO
Developer of a biotechnology company designed to advance new methods in natural killer cell-based immunotherapy for cancer treatment. The company develops cell therapies and small molecule drugs that promote robust cell expansion and tumor-killing activity, enabling physicians and oncology clinics with innovative therapeutic options that aim to improve cancer targeting, address resistance to standard treatments, and enhance patient outcomes in oncology care.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 11
- Website
- nk-io.com/
- Ownership
- Privately Held (backing)
NK:IO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NK:IO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NK:IO in its N-PORT filings yet. We sweep new filings monthly.